ORIC
Oric Pharmaceuticals Inc.
$13.16
-$0.18(-1.35%)
54
Overall
60
Value
72
Tech
31
Quality
Market Cap
$1.30B
Volume
1.17M
52W Range
$3.90 - $14.93
Target Price
$18.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $74.2M | $78.9M | $86.8M | $110.8M | $142.9M | ||
| Research & Development | $60.8M | $56.9M | $61.7M | $85.2M | $114.1M | ||
| Research Expense | $60.8M | $56.9M | $61.7M | $85.2M | $114.1M | ||
| Selling, General & Administrative | $13.4M | $22.0M | $25.1M | $25.6M | $28.8M | ||
| General & Administrative Expenses | $13.4M | $22.0M | $25.1M | $25.6M | $28.8M | ||
| Salaries & Wages | -- | -- | -- | $15.2M | $20.2M | ||
| Depreciation & Amortization | $1.0M | $900.0K | $1.0M | $1.0M | $1.1M | ||
| Depreciation & Amortization | $1.0M | $900.0K | $1.0M | $1.0M | $1.1M | ||
| Other Operating Expenses | $1.4M | $1.8M | $-5.0M | $-639.0K | $-926.0K | ||
| OPERATING INCOME | |||||||
| Operating income | $-74.2M | $-78.9M | $-91.8M | $-110.8M | $-142.9M | ||
| EBITDA | $-48.4M | $-78.0M | $-85.8M | $-106.6M | $-135.4M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $306.0K | $141.0K | $2.6M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $306.0K | $141.0K | $-2.6M | -- | -- | ||
| Other Income/Expense | $-177.0K | $-15.0K | $-2.4M | $-10.1M | $-15.0M | ||
| Other Special Charges | $177.0K | $15.0K | $2.6M | $10.1M | $15.0M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-49.3M | $-78.9M | $-86.8M | $-107.6M | $-136.5M | ||
| Pre-Tax Income | $-73.7M | $-78.7M | $-89.1M | $-100.7M | $-127.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $-5.2M | $-5.4M | $-6.0M | $-6.9M | $-8.7M | ||
| NET INCOME | |||||||
| Net Income | $-73.7M | $-78.7M | $-89.1M | $-100.7M | $-127.8M | ||
| Net Income (Continuing Operations) | $-73.7M | $-78.7M | $-89.1M | $-100.7M | $-127.8M | ||
| Net Income (Discontinued Operations) | $-73.7M | $-78.7M | $-89.1M | $-100.7M | $-127.8M | ||
| Net Income (Common Stockholders) | $-73.7M | $-78.7M | $-89.1M | $-100.7M | $-127.8M | ||
| Normalized Income | -- | $-84.1M | -- | -- | $-136.5M | ||
| TOTALS | |||||||
| Total Expenses | $74.2M | $78.9M | $86.8M | $110.8M | $142.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $21.9M | $38.0M | $39.7M | $51.5M | $69.7M | ||
| Average Shares Outstanding (Diluted) | $21.9M | -- | $39.7M | $51.5M | $69.7M | ||
| Shares Outstanding | $36.7M | $39.4M | $45.1M | $67.4M | $71.0M | ||
| Basic EPS | $-3.36 | $-2.07 | $-2.25 | $-1.96 | $-1.83 | ||
| Basic EPS (Continuing Operations) | $-3.36 | $-2.07 | $-2.25 | $-1.96 | $-1.83 | ||
| Diluted EPS | $-3.36 | $-2.07 | $-2.25 | $-1.96 | $-1.83 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.25 | $-1.96 | $-1.83 | ||
| OTHER METRICS | |||||||
| Other Gand A | $13.4M | $22.0M | $25.1M | $25.6M | $28.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORIC | $13.16 | -1.3% | 1.17M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Oric Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW